Laboratory Company Top Insiders
LH Stock | USD 241.29 1.62 0.68% |
Laboratory's insiders are aggressively selling. The analysis of insiders' sentiment of trading Laboratory of stock suggests that almost all insiders are panicking at this time. Laboratory employs about 67 K people. The company is managed by 34 executives with a total tenure of roughly 156 years, averaging almost 4.0 years of service per executive, having 1970.59 employees per reported executive.
Adam Schechter Chairman Chairman of the Board, President, Chief Executive Officer |
Glenn Eisenberg President Chief Financial Officer, Executive Vice President |
Laboratory's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-11 | Adam H Schechter | Disposed 6189 @ 243.47 | View | ||
2024-10-24 | Kerrii B Anderson | Disposed 1000 @ 230 | View | ||
2024-08-19 | Der Vaart Sandra D Van | Disposed 2000 @ 227.05 | View | ||
2024-08-15 | Glenn A Eisenberg | Disposed 15000 @ 223.99 | View | ||
2024-08-08 | Kerrii B Anderson | Disposed 586 @ 225 | View | ||
2024-08-05 | Lance Berberian | Disposed 12093 @ 229.1 | View | ||
2024-05-14 | Der Vaart Sandra D Van | Disposed 2000 @ 210.83 | View | ||
2024-05-02 | Kerrii B Anderson | Disposed 250 @ 200.1 | View | ||
2024-04-30 | Kerrii B Anderson | Disposed 250 @ 204.13 | View | ||
2024-04-29 | Peter J Wilkinson | Disposed 2439 @ 204.33 | View | ||
2024-04-01 | Amy B Summy | Disposed 3500 @ 217.29 | View | ||
2024-03-28 | Der Vaart Sandra D Van | Disposed 3553 @ 216.74 | View | ||
2024-03-07 | Mark S Schroeder | Disposed 5048 @ 218.45 | View | ||
2024-02-21 | Jonathan P Divincenzo | Disposed 500 @ 215.49 | View | ||
2024-02-13 | Der Vaart Sandra D Van | Disposed 237 @ 226.45 | View | ||
2024-02-08 | Der Vaart Sandra D Van | Disposed 259 @ 222.06 | View |
Monitoring Laboratory's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Laboratory |
Laboratory's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Laboratory's future performance. Based on our forecasts, it is anticipated that Laboratory will maintain a workforce of under 67000 employees by December 2024.Laboratory's latest congressional trading
Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
2024-07-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2020-08-12 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
2019-05-03 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Laboratory Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0396 % which means that for every $100 of assets, it generated a profit of $0.0396. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0543 %, which means that it produced $0.0543 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.05. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.The Laboratory's current Common Stock Shares Outstanding is estimated to increase to about 96 M. The Laboratory's current Net Income Applicable To Common Shares is estimated to increase to about 1.5 B
Laboratory Workforce Comparison
Laboratory of is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 296,190. Laboratory totals roughly 67,000 in number of employees claiming about 23% of equities under Health Care industry.
Laboratory Profit Margins
The company has Net Profit Margin (PM) of 0.03 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.08 %, which signifies that for every $100 of sales, it has a net operating income of $0.08.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.42 | 0.2767 |
|
| |||||
Net Profit Margin | 0.0674 | 0.0344 |
|
| |||||
Operating Profit Margin | 0.0567 | 0.0597 |
|
| |||||
Pretax Profit Margin | 0.0444 | 0.0468 |
|
| |||||
Return On Assets | 0.0237 | 0.025 |
|
| |||||
Return On Equity | 0.0504 | 0.0531 |
|
|
Laboratory Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Laboratory insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 1.0 | 2 | 2 | 2,220 | 7,189 |
2024-06-01 | 0.2857 | 4 | 14 | 21,380 | 45,357 |
2024-03-01 | 0.8056 | 87 | 108 | 303,211 | 297,981 |
2023-12-01 | 0.5 | 2 | 4 | 436.00 | 1,839 |
2023-09-01 | 0.3333 | 1 | 3 | 56.00 | 5,073 |
2023-06-01 | 2.0 | 22 | 11 | 158,353 | 15,832 |
2023-03-01 | 0.9111 | 82 | 90 | 225,878 | 89,157 |
2022-12-01 | 0.7273 | 8 | 11 | 38,739 | 30,103 |
2022-09-01 | 0.2941 | 5 | 17 | 32,917 | 104,216 |
2022-03-01 | 0.9186 | 79 | 86 | 156,968 | 58,112 |
2021-12-01 | 0.2941 | 5 | 17 | 17,058 | 26,724 |
2021-09-01 | 0.5 | 2 | 4 | 4,550 | 9,065 |
2021-06-01 | 0.4286 | 3 | 7 | 8,110 | 18,162 |
2021-03-01 | 0.9 | 72 | 80 | 135,493 | 47,163 |
2020-12-01 | 0.4286 | 6 | 14 | 17,229 | 27,598 |
2020-09-01 | 0.5 | 3 | 6 | 2,420 | 5,443 |
2020-06-01 | 0.2 | 1 | 5 | 1,010 | 33,504 |
2020-03-01 | 0.9605 | 73 | 76 | 293,460 | 118,837 |
2019-12-01 | 1.0 | 9 | 9 | 147,524 | 36,645 |
2019-09-01 | 0.2222 | 2 | 9 | 5,066 | 26,216 |
2019-06-01 | 0.5263 | 10 | 19 | 148,322 | 92,882 |
2019-03-01 | 0.8906 | 57 | 64 | 197,097 | 73,462 |
2018-12-01 | 0.5 | 2 | 4 | 6,874 | 8,360 |
2018-09-01 | 0.25 | 1 | 4 | 153.00 | 2,306 |
2018-06-01 | 0.25 | 5 | 20 | 128,553 | 253,615 |
2018-03-01 | 0.8947 | 68 | 76 | 341,205 | 239,230 |
2017-09-01 | 0.381 | 8 | 21 | 213,123 | 439,693 |
2017-06-01 | 0.8 | 4 | 5 | 17,432 | 11,573 |
2017-03-01 | 0.8312 | 64 | 77 | 350,653 | 176,413 |
2016-12-01 | 1.0 | 2 | 2 | 49,901 | 31,601 |
2016-09-01 | 0.2 | 1 | 5 | 992.00 | 11,161 |
2016-06-01 | 0.3 | 3 | 10 | 200,450 | 411,918 |
2016-03-01 | 0.7179 | 56 | 78 | 312,339 | 252,898 |
2015-12-01 | 0.25 | 2 | 8 | 3,146 | 6,006 |
2015-09-01 | 0.375 | 3 | 8 | 119,990 | 229,576 |
2015-06-01 | 0.2632 | 5 | 19 | 57,060 | 113,853 |
2015-03-01 | 0.6667 | 44 | 66 | 144,102 | 159,333 |
2014-12-01 | 0.3333 | 1 | 3 | 624.00 | 1,718 |
2014-09-01 | 0.3 | 3 | 10 | 195,700 | 393,400 |
2014-06-01 | 1.1053 | 21 | 19 | 127,379 | 191,432 |
2014-03-01 | 0.4138 | 12 | 29 | 125,329 | 145,306 |
2013-12-01 | 0.6 | 6 | 10 | 100,024 | 188,800 |
2013-09-01 | 0.5 | 4 | 8 | 100,000 | 132,429 |
2013-06-01 | 0.6296 | 17 | 27 | 320,270 | 584,451 |
2013-03-01 | 0.4706 | 8 | 17 | 105,453 | 41,638 |
2012-09-01 | 0.625 | 5 | 8 | 149,294 | 254,830 |
2012-06-01 | 3.0 | 9 | 3 | 285,700 | 5,687 |
2012-03-01 | 0.5 | 15 | 30 | 260,005 | 274,061 |
2011-12-01 | 0.5 | 1 | 2 | 20,000 | 40,000 |
2011-09-01 | 0.6667 | 2 | 3 | 1,353 | 2,170 |
2011-06-01 | 1.3333 | 12 | 9 | 22,792 | 22,909 |
2011-03-01 | 0.6207 | 18 | 29 | 438,936 | 102,157 |
2010-12-01 | 0.375 | 3 | 8 | 65,366 | 132,494 |
2010-09-01 | 0.75 | 3 | 4 | 14,096 | 4,716 |
2010-06-01 | 1.4286 | 10 | 7 | 31,000 | 36,686 |
2010-03-01 | 0.65 | 13 | 20 | 487,600 | 78,161 |
2009-12-01 | 0.2 | 1 | 5 | 4,116 | 22,080 |
2009-09-01 | 1.0 | 2 | 2 | 50,700 | 854.00 |
2009-06-01 | 2.0 | 8 | 4 | 19,200 | 33,707 |
2009-03-01 | 0.5217 | 12 | 23 | 608,000 | 25,320 |
2008-06-01 | 0.371 | 23 | 62 | 568,776 | 12,548 |
2008-03-01 | 0.0755 | 33 | 437 | 354,093 | 385,564 |
2007-12-01 | 0.7143 | 15 | 21 | 35,260 | 72,386 |
2007-09-01 | 1.5455 | 17 | 11 | 95,452 | 95,856 |
2007-06-01 | 0.3218 | 28 | 87 | 39,074 | 82,599 |
2007-03-01 | 0.3179 | 48 | 151 | 631,190 | 228,173 |
2006-12-01 | 1.3636 | 15 | 11 | 14,288 | 28,000 |
2006-09-01 | 1.0556 | 19 | 18 | 27,060 | 53,993 |
2006-06-01 | 0.5962 | 31 | 52 | 90,974 | 170,945 |
2006-03-01 | 0.1429 | 57 | 399 | 976,027 | 1,306,343 |
2005-12-01 | 1.6667 | 15 | 9 | 13,996 | 29,233 |
2005-09-01 | 2.25 | 18 | 8 | 61,125 | 121,546 |
2005-06-01 | 0.7273 | 32 | 44 | 101,455 | 174,097 |
2005-03-01 | 0.1489 | 35 | 235 | 505,023 | 713,208 |
2004-12-01 | 0.5972 | 43 | 72 | 546,198 | 1,089,771 |
2004-09-01 | 9.0 | 18 | 2 | 3,303 | 286.00 |
2004-06-01 | 0.6735 | 33 | 49 | 143,456 | 206,000 |
2004-03-01 | 0.1051 | 29 | 276 | 691,714 | 812,942 |
2003-12-01 | 0.6154 | 16 | 26 | 64,604 | 70,000 |
2003-09-01 | 0.6 | 12 | 20 | 19,700 | 62,962 |
Laboratory Notable Stakeholders
A Laboratory stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Laboratory often face trade-offs trying to please all of them. Laboratory's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Laboratory's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul Kirchgraber | Executive Vice President and Chief Executive Officer - Covance Drug Development | Profile | |
Adam Schechter | Chairman of the Board, President, Chief Executive Officer | Profile | |
Glenn Eisenberg | Chief Financial Officer, Executive Vice President | Profile | |
Lance Berberian | Executive Vice President, Chief Technology Officer, Chief Information Officer | Profile | |
JD MD | President EVP | Profile | |
Peter Wilkinson | Senior Vice President, Chief Accounting Officer | Profile | |
Brian Caveney | Executive Vice President, President, Diagnostics and Chief Medical Officer | Profile | |
Sandra Vaart | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | Profile | |
Kerrii Anderson | Independent Director | Profile | |
JeanLuc Belingard | Independent Director | Profile | |
Peter Neupert | Lead Independent Director | Profile | |
Richelle Parham | Independent Director | Profile | |
Robert Williams | Independent Director | Profile | |
Jeffrey Davis | Independent Director | Profile | |
Garheng Kong | Independent Director | Profile | |
Marcia Eisenberg | Enterprise VP | Profile | |
Sandra JD | Chief VP | Profile | |
Deborah SesokPizzini | SVP Officer | Profile | |
Akinbolade Oyegunwa | Executive Officer | Profile | |
Anita Graham | Executive Officer | Profile | |
Judith Seltz | Chief Human Resource Officer, Executive Vice President | Profile | |
Michelle Abelson | Laboratory Operations | Profile | |
Jonathan DiVincenzo | Executive International | Profile | |
Amy Summy | Executive Vice President Chief Marketing Officer | Profile | |
Mark Schroeder | Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | Profile | |
Robert Pringle | Senior Treasurer | Profile | |
Paul MD | Ex Devel | Profile | |
John Treadwell | Vice Initiatives | Profile | |
D Gilliland | Independent Director | Profile | |
Kathryn Wengel | Independent Director | Profile | |
Christin ODonnell | Vice Relations | Profile | |
Megan MPH | Executive Officer | Profile | |
Chas Cook | VP Relations | Profile | |
MPH MD | Pres VP | Profile |
About Laboratory Management Performance
The success or failure of an entity such as Laboratory often depends on how effective the management is. Laboratory management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Laboratory management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Laboratory management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.06 | 0.05 | |
Return On Capital Employed | 0.05 | 0.05 | |
Return On Assets | 0.02 | 0.02 | |
Return On Equity | 0.05 | 0.05 |
Laboratory Workforce Analysis
Traditionally, organizations such as Laboratory use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Laboratory within its industry.Laboratory Manpower Efficiency
Return on Laboratory Manpower
Revenue Per Employee | 181.5K | |
Revenue Per Executive | 357.7M | |
Net Income Per Employee | 5.7K | |
Net Income Per Executive | 11.2M | |
Working Capital Per Employee | 8.1K | |
Working Capital Per Executive | 15.9M |
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Transaction History View history of all your transactions and understand their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Fundamental Analysis View fundamental data based on most recent published financial statements |